Saphenous vein grafts, along with the left internal thoracic artery graft, are the hallmark of coronary artery bypass grafting (CABG). Grounded on vast and landmark evidence, this technique remains a successful strategy for decades, with a significant advantage over medical or percutaneous intervention in treating advanced coronary artery disease (CAD), affording patients improved survival, reduction of myocardial infarction rates, and relief on angina symptoms. However, the superior outcomes seen in coronary surgery are directly related to the graft’s ability to remain patent over the long term, averting spontaneous myocardium infarction, the main cause of death in CAD patients, besides relieving angina. Offering the possibility of enhanced graft patency is consequently crucial for extending benefits and prolonging survival. Recently, tremendous efforts have been made in such a direction, pushing for wider utilization of arterial grafts. But the multiple arterial grafts (MAG) strategy has been met by coronary surgeons with skepticism and reluctance due to higher complications rate and resulting in low adherence practice [1]. The introduction of the no-touch saphenous vein (NTSV) graft, at first met with discredit and hesitancy, has been demonstrated by solid evidence (randomized controlled trials and meta-analyses) to offer superior patency than conventionally harvested vein graft over the long term, and comparable or even superior to MAGs [2, 3]. The NT-SV technique is attractive because of the possibility of using a time-honored graft, familiar to all coronary surgeons, seemingly with a little change in harvesting technique. However, intrinsic and related complications with the